Comparative Pharmacology
Head-to-head clinical analysis: LOXITANE IM versus TINDAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LOXITANE IM versus TINDAL.
LOXITANE IM vs TINDAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
LOXITANE IM (loxapine) is a dibenzoxazepine antipsychotic. Its mechanism of action is not fully established but is thought to be mediated via antagonism of central dopamine D2 and serotonin 5-HT2A receptors. It has high affinity for D2, D3, D4, and 5-HT2A receptors and low affinity for D1 receptors. It also has moderate affinity for histamine H1 and alpha1-adrenergic receptors.
TINDAL (trimethoprim) inhibits bacterial dihydrofolate reductase (DHFR), preventing the reduction of dihydrofolate to tetrahydrofolate, thereby inhibiting bacterial DNA synthesis.
Adults: 12.5-50 mg IM every 4-6 hours as needed, not to exceed 150 mg/day.
TINDAL (ticarcillin disodium + clavulanate potassium) 3.1 g (ticarcillin 3 g + clavulanic acid 0.1 g) IV every 4-6 hours. Maximum dose: 18 g ticarcillin/0.6 g clavulanic acid per day.
None Documented
None Documented
Terminal elimination half-life: 8-12 hours. Clinically, steady-state reached in 2-3 days; dosing interval based on q6-12h.
Terminal elimination half-life is approximately 12-15 hours in adults with normal renal function; prolonged in renal impairment.
Primarily renal: 70% as metabolites; biliary/fecal: 30% as metabolites and unchanged drug.
Primarily renal excretion of unchanged drug (70-80%) and hepatic metabolism (20-30%).
Category C
Category C
Antipsychotic
Antipsychotic